Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Clinuvel Pharmaceuticals Limited
  6. Company
    CUV   AU000000CUV3

CLINUVEL PHARMACEUTICALS LIMITED

(CUV)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 10/18
40.48 AUD   -1.53%
10/17CLINUVEL PHARMACEUTICALS : Investor Webinar
PU
10/06CLINUVEL PHARMACEUTICALS : Operations Update Webcast II
PU
10/05Australia shares nearly flat as financials' losses offset tech, healthcare gains
RE
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). It is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
Sales per Business
20202021Delta
Biopharmaceutical Products32.57100%47.98100% +47.32%
AUD in Million
Sales per region
2021
European Economic Area and United States42.7489.1%
Switzerland Others5.2310.9%
AUD in Million
Managers
Name Title Age Since
Philippe Jacques Wolgen, Dr. Chief Executive Officer, MD & Director 57 2005
Darren M. Keamy Chief Financial Officer & Secretary - -
Dennis J. Wright, Dr. Chief Scientific Officer - -
Lachlan Hay Global Director-Operations - -
Brenda Mary Shanahan Independent Non-Executive Director - 2007
Willem A. Blijdorp Chairman 68 2019
Karen Agersborg, Dr. Independent Non-Executive Director - 2018
Members of the board
Name Title Age Since
Willem A. Blijdorp Chairman 68 2019
Philippe Jacques Wolgen, Dr. Chief Executive Officer, MD & Director 57 2005
Brenda Mary Shanahan Independent Non-Executive Director - 2007
Karen Agersborg, Dr. Independent Non-Executive Director - 2018
Susan Smith Non-Executive Director - 2019
Jeffrey Rosenfeld Non-Executive Director - 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 49,410,338 39,108,483 79.2% 0 0.0% 79.2%
Shareholders
NameEquities%
Philippe Jacques Wolgen 3,755,551 7.60%
Ender 1 LLC 2,590,824 5.24%
Willem A. Blijdorp 1,743,118 3.53%
Mark Edwin Badcock 1,180,510 2.39%
The Vanguard Group, Inc. 1,135,364 2.30%
Capital Research & Management Co. (World Investors) 941,000 1.90%
Vanguard Investments Australia Ltd. 616,012 1.25%
Norges Bank Investment Management 510,985 1.03%
BlackRock Fund Advisors 470,444 0.95%
Darren M. Keamy 363,878 0.74%
Company contact information
Clinuvel Pharmaceuticals Ltd.
535 Bourke Street
Level 11
Melbourne, Victoria (VIC) 3000

Phone : +61.3.9660.4900
Fax : +3.9660.4909
Web : http://www.clinuvel.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Clinuvel Pharmaceuticals Limited